GlassScriptPhysician profile
Matthew G Potter
NPI 1578004305
$1,946.49
in general payments reported to CMS, 2019-2025
26 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $339 · 2023: $608 · 2024: $590 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $399.15 | 2021-2024 | Vumerity, Tysabri |
| Ucb, INC. | $184.83 | 2022-2025 | Rystiggo, Briviact |
| Lilly USA, LLC | $151.38 | 2022-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $132.64 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $130.04 | 2023 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $115.79 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $112.37 | 2024 | |
| Alexion Pharmaceuticals, INC. | $99.13 | 2022-2024 | Ultomiris |
| Kyowa Kirin, INC. | $97.47 | 2024 | Nourianz |
| Daiichi Sankyo INC. | $91.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.06 | 2021-2025 | Glassia |
| Lundbeck LLC | $49.29 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $48.60 | 2021-2022 | |
| Abbvie INC. | $43.79 | 2023-2025 | |
| Amgen INC. | $32.82 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.73 | 2021-2024 | Xifaxan |
| Emd Serono, INC. | $21.83 | 2023 | Mavenclad |
| Boston Scientific Corporation | $21.59 | 2024 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $19.82 | 2022 | |
| Livanova USA, INC. | $18.76 | 2022 | |
| Novo Nordisk INC | $17.63 | 2021 | |
| Braeburn INC. | $16.59 | 2025 | Brixadi |
| Csl Behring | $14.96 | 2022 | |
| Exact Sciences Corporation | $13.68 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2022 | |
| Merck Sharp & Dohme LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.